Coalition submits formal comment on FDA Draft Guidance on “Presenting Risk Information in Prescription Drug and Medical Device Promotion”.
The coalition’s comment, which commends the draft’s many strong points, also criticizes what they believe is the FDA’s over complication of advertising and promotion.
Read the full comment
FDA Draft Guidance: Coalition Submits Formal Comment
Coalition submits formal comment on FDA Draft Guidance on “Presenting Risk Information in Prescription Drug and Medical Device Promotion”.
The coalition’s comment, which commends the draft’s many strong points, also criticizes what they believe is the FDA’s over complication of advertising and promotion.
Read the full comment
Related Posts
Summary, Analysis and Recommendations on the Administration’s Announcements to Limit Rx Ads
Fact Sheet on the Benefits of Healthcare Communication & Marketing
Oklahoma Bill Would Broadly Ban DTC Pharmaceutical Advertising